Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
ROSG's Cash to Debt is ranked higher than
93% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.70 vs. ROSG: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ROSG' s Cash to Debt Range Over the Past 10 Years
Min: 0.77  Med: 726.72 Max: No Debt
Current: No Debt
Equity to Asset 0.82
ROSG's Equity to Asset is ranked higher than
89% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. ROSG: 0.82 )
Ranked among companies with meaningful Equity to Asset only.
ROSG' s Equity to Asset Range Over the Past 10 Years
Min: -0.27  Med: 0.68 Max: 0.88
Current: 0.82
-0.27
0.88
Z-Score: -7.38
WACC vs ROIC
6.28%
-215.59%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -151.10
ROSG's Operating margin (%) is ranked lower than
78% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.99 vs. ROSG: -151.10 )
Ranked among companies with meaningful Operating margin (%) only.
ROSG' s Operating margin (%) Range Over the Past 10 Years
Min: -9864.67  Med: -3704.25 Max: -190.14
Current: -151.1
-9864.67
-190.14
Net-margin (%) -166.01
ROSG's Net-margin (%) is ranked lower than
79% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.63 vs. ROSG: -166.01 )
Ranked among companies with meaningful Net-margin (%) only.
ROSG' s Net-margin (%) Range Over the Past 10 Years
Min: -11003.33  Med: -4193.47 Max: -209.78
Current: -166.01
-11003.33
-209.78
ROE (%) -120.90
ROSG's ROE (%) is ranked lower than
85% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.04 vs. ROSG: -120.90 )
Ranked among companies with meaningful ROE (%) only.
ROSG' s ROE (%) Range Over the Past 10 Years
Min: -545.27  Med: -84.49 Max: -47.3
Current: -120.9
-545.27
-47.3
ROA (%) -103.26
ROSG's ROA (%) is ranked lower than
88% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.78 vs. ROSG: -103.26 )
Ranked among companies with meaningful ROA (%) only.
ROSG' s ROA (%) Range Over the Past 10 Years
Min: -240.7  Med: -78.20 Max: -40.87
Current: -103.26
-240.7
-40.87
ROC (Joel Greenblatt) (%) -245.03
ROSG's ROC (Joel Greenblatt) (%) is ranked lower than
67% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.88 vs. ROSG: -245.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ROSG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1823.73  Med: -1084.62 Max: -199.41
Current: -245.03
-1823.73
-199.41
Revenue Growth (3Y)(%) 130.10
ROSG's Revenue Growth (3Y)(%) is ranked higher than
98% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. ROSG: 130.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ROSG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -70.00 Max: 130.1
Current: 130.1
0
130.1
EBITDA Growth (3Y)(%) -21.60
ROSG's EBITDA Growth (3Y)(%) is ranked lower than
79% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. ROSG: -21.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ROSG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -70.8  Med: -29.70 Max: -2.6
Current: -21.6
-70.8
-2.6
EPS Growth (3Y)(%) -21.70
ROSG's EPS Growth (3Y)(%) is ranked lower than
73% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.10 vs. ROSG: -21.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ROSG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -69.9  Med: -30.50 Max: 3.4
Current: -21.7
-69.9
3.4
» ROSG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

ROSG Guru Trades in

ROSG Guru Trades in

Q3 2014

ROSG Guru Trades in Q3 2014

Jim Simons 18,400 sh (New)
» More
Q4 2014

ROSG Guru Trades in Q4 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ROSG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:OTCBB:AVDX, OTCPK:CBIS, LSE:NIPT, HKSE:08247, NAS:CGIX, OTCPK:MHTX » details
Traded in other countries:RQ1.Germany,
Rosetta Genomics Ltd is engaged in the development and commercialization of new diagnostic tests and therapeutics based on a group of genes known as microRNAs.

Rosetta Genomics, Ltd., develops diagnostic tests and therapeutic tools. Its product portfolio comprises of tests such as miRview mets2/mets, miRview squamous, miRview meso and miRview kidney.

Ratios

vs
industry
vs
history
Price/Owner Earnings (ttm) 2.69
ROSG's Price/Owner Earnings (ttm) is ranked higher than
98% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.47 vs. ROSG: 2.69 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ROSG' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 1.02  Med: 4.34 Max: 10.39
Current: 2.69
1.02
10.39
P/B 1.45
ROSG's P/B is ranked higher than
90% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. ROSG: 1.45 )
Ranked among companies with meaningful P/B only.
ROSG' s P/B Range Over the Past 10 Years
Min: 0.48  Med: 2.49 Max: 37.02
Current: 1.45
0.48
37.02
P/S 1.67
ROSG's P/S is ranked higher than
66% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.95 vs. ROSG: 1.67 )
Ranked among companies with meaningful P/S only.
ROSG' s P/S Range Over the Past 10 Years
Min: 1.42  Med: 30.91 Max: 200.29
Current: 1.67
1.42
200.29
EV-to-EBIT -0.61
ROSG's EV-to-EBIT is ranked lower than
99.99% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.15 vs. ROSG: -0.61 )
Ranked among companies with meaningful EV-to-EBIT only.
ROSG' s EV-to-EBIT Range Over the Past 10 Years
Min: -12.4  Med: -0.60 Max: 0.4
Current: -0.61
-12.4
0.4
EV-to-EBITDA -0.61
ROSG's EV-to-EBITDA is ranked lower than
99.99% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.21 vs. ROSG: -0.61 )
Ranked among companies with meaningful EV-to-EBITDA only.
ROSG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.4  Med: -0.60 Max: 0.4
Current: -0.61
-12.4
0.4
Current Ratio 4.73
ROSG's Current Ratio is ranked higher than
85% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. ROSG: 4.73 )
Ranked among companies with meaningful Current Ratio only.
ROSG' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 6.91 Max: 26.26
Current: 4.73
1.14
26.26
Quick Ratio 4.73
ROSG's Quick Ratio is ranked higher than
88% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. ROSG: 4.73 )
Ranked among companies with meaningful Quick Ratio only.
ROSG' s Quick Ratio Range Over the Past 10 Years
Min: 1.14  Med: 6.91 Max: 26.26
Current: 4.73
1.14
26.26
Days Sales Outstanding 108.36
ROSG's Days Sales Outstanding is ranked lower than
91% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ROSG: 108.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
ROSG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.98  Med: 159.80 Max: 885.73
Current: 108.36
38.98
885.73
Days Payable 62.81
ROSG's Days Payable is ranked higher than
55% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 56.90 vs. ROSG: 62.81 )
Ranked among companies with meaningful Days Payable only.
ROSG' s Days Payable Range Over the Past 10 Years
Min: 62.27  Med: 562.16 Max: 1066.71
Current: 62.81
62.27
1066.71

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 1.45
ROSG's Price/Tangible Book is ranked higher than
92% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.35 vs. ROSG: 1.45 )
Ranked among companies with meaningful Price/Tangible Book only.
ROSG' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.88  Med: 2.61 Max: 26.84
Current: 1.45
0.88
26.84
Earnings Yield (Greenblatt) (%) -163.90
ROSG's Earnings Yield (Greenblatt) (%) is ranked lower than
92% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.40 vs. ROSG: -163.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ROSG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -145.65  Med: 182.90 Max: 691
Current: -163.9
-145.65
691

More Statistics

Revenue (TTM) (Mil) $10.55
EPS (TTM) $ -1.03
Beta0.59
Short Percentage of Float3.56%
52-Week Range $0.71 - 3.97
Shares Outstanding (Mil)20.85

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 13 19 26
EPS($) -0.73 -0.55 -0.37
EPS without NRI($) -0.73 -0.55 -0.37
» More Articles for ROSG

Headlines

Articles On GuruFocus.com
Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $ Dec 08 2008 

More From Other Websites
Rosetta Genomics Receives Approval from New York State for Four PCR-based Assays May 23 2016
8:05 am Rosetta Genomics receives conditional approval from the NY State Department of Health for... May 23 2016
Rosetta Genomics Receives Approval from New York State for Four PCR-Based Assays May 23 2016
Edited Transcript of ROSG earnings conference call or presentation 19-May-16 2:00pm GMT May 19 2016
Rosetta Genomics Reports 2016 First Quarter Results May 19 2016
Rosetta Genomics Reports 2016 First Quarter Financial Results May 19 2016
Q1 2016 Rosetta Genomics Ltd Earnings Release - Before Market Open May 19 2016
Rosetta Genomics to Host 2016 First Quarter Financial and Business Update Conference Call on May 19,... May 16 2016
Rosetta Genomics to Host 2016 First Quarter Financial Results and Business Update Conference Call on... May 16 2016
Rosetta Genomics Ltd. :ROSG-US: Earnings Analysis: Q4, 2015 By the Numbers Apr 13 2016
Rosetta Genomics Ltd. :ROSG-US: Earnings Analysis: 2015 By the Numbers Apr 13 2016
ROSETTA GENOMICS LTD. Financials Mar 29 2016
ROSG: Revenue Growth Accelerated in 4Q15 Mar 28 2016
Rosetta Genomics Reports 2015 Full Year Financial Results Mar 23 2016
Rosetta Genomics Reports 2015 Full Year Financial Results Mar 23 2016
Full Year 2015 Rosetta Genomics Ltd Earnings Release - Time Not Supplied Mar 23 2016
Rosetta Genomics to Host Business Update and 2015 Year-End Financial Results Conference Call on... Mar 17 2016
Rosetta Genomics Appoints Ana C. Ward as Executive Vice President, Legal and Corporate Development Feb 29 2016
Rosetta Genomics Expands Molecular Diagnostics Test Menu with Launch of Three New Product Offerings Feb 25 2016
Rosetta Genomics Receives Approval from New York State for First-of-its-kind Thyroid Cancer... Feb 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)